Rocket Lab Stock Is Down 14%. Is It Finally Time to Buy?

Rocket Lab has a $1.85 billion backlog and is expanding beyond small-lift launches, with analysts projecting revenue of $870 million this year and $1.2 billion in 2027. A January fuel tank rupture delayed Neutron to Q4 this year, but the company also signed a $190 million defense contract for 20 hypersonic test flights and added three Electron launches for iQPS starting in 2028. The setback is a near-term headwind, but the contract wins and growing space systems business support a positive long-term outlook.

Analysis

Rocket Lab’s setup is less about a near-term launch cadence story and more about a credibility premium being re-priced into a platform company. The market is likely underestimating how much of the equity value is tied to Neutron optionality: even modest delays defer the re-rating from a niche launch operator to a broader defense/space prime with higher gross-margin mix. In the meantime, the business is being buffered by contract visibility and by the fact that launch delays can actually strengthen pricing discipline if customers view capacity as scarce rather than abundant.

The second-order effect is competitive, not binary. SpaceX remains the gravitational center of the sector, but Rocket Lab is increasingly positioning itself as the default “non-SpaceX” vendor for government and allied demand, which matters if procurement buyers want concentration risk reduction. That can spill over into adjacent suppliers and integrators: any company tied to hypersonics, satellite deployment hardware, or defense payload processing could see incremental demand as Rocket Lab monetizes the trust advantage it has built.

The key risk is that the stock is being priced on a smooth execution path while the path to Neutron is inherently lumpy. Another delay would likely hit the multiple harder than the cash-flow outlook because the bull case depends on narrative transition, not just incremental revenue. Near-term catalysts are contract wins and launch cadence over the next 2-3 quarters; the downside catalyst is a second technical setback that pushes the “growth platform” story into 2027.

Contrarian view: the consensus may be too focused on Neutron as the sole catalyst and underappreciating the strength of the existing systems and defense stack as the cleaner monetization path. If the market waits for flawless Neutron execution, it may miss that Rocket Lab can compound value through recurring government work and high-attach-rate components, which reduces dependence on launch timing and makes the business less binary than the stock implies.

Key Decisions for Investors

• Initiate a tactical long RKLB position on weakness, with a 6-12 month horizon and a stop tied to any further Neutron delay; risk/reward is attractive because the downside from a delay is visible, while upside from even one successful Neutron milestone can re-rate the multiple meaningfully.
• Use call spreads in RKLB instead of outright stock for the next 3-6 months: the thesis is event-driven and convex, but execution risk is high enough that defined risk is preferable to uncapped downside.
• Pair trade: long RKLB / short a basket of lower-quality space-adjacent small caps with weaker backlog and less defense exposure; this isolates execution and contract-quality alpha rather than a broad sector beta bet.
• Add exposure only after confirmation of either a clean test sequence or another defense contract win; if the next catalyst is contract-led rather than launch-led, the market may be forced to value the company more like an infrastructure-defense compounder than a pre-profit launch story.